Inspira Lands Vendor Approval from $12B HMO, Opens ART100 to 4.9M Members
Inspira Technologies has secured vendor approval from Clalit Health Services, a $12 billion revenue HMO serving approximately 4.9 million members across 14 hospitals and 1,600 clinics. This approval authorizes immediate ART100 procurement and deployment following rigorous clinical and technical review by Clalit’s Medical Equipment Committee.
1. Clalit Approval Details
Inspira Technologies received vendor approval from Clalit Health Services’ Medical Equipment Committee, enabling official procurement and operational use of the ART100 system. Clalit, with $12 billion revenue and recognized as the world’s second-largest integrated HMO, granted approval after detailed clinical evaluation by its thoracic and cardiac surgery committee.
2. Scale of Deployment
Approval covers Clalit’s network of approximately 4.9 million members, including 14 hospitals—such as Rabin and Soroka Medical Centers—and over 1,600 ambulatory clinics. This integration permits immediate ART100 deployment across a sophisticated healthcare supply chain, streamlining procurement under Clalit’s established protocols.
3. Commercial Impact and Outlook
This vendor status marks a key commercial inflection point for Inspira Technologies, offering a reference case in a major integrated health system comparable to leading U.S. networks. The company expects this validation to accelerate ART100 adoption in the U.S. and other global markets, potentially driving significant long-term revenue growth.